Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Accumulated Depreciation & Amortization (2016 - 2025)

Protalix BioTherapeutics has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $37.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $37.0 million for Q4 2025, up 3.66% from a year ago — trailing twelve months through Dec 2025 was $37.0 million (up 3.66% YoY), and the annual figure for FY2025 was $37.0 million, up 3.66%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $37.0 million at Protalix BioTherapeutics, up from $35.7 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for PLX hit a ceiling of $37.0 million in Q4 2025 and a floor of $32.8 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $34.7 million (2023), compared with a mean of $34.8 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 2.6% in 2021 and later increased 3.66% in 2025.
  • Protalix BioTherapeutics' Accumulated Depreciation & Amortization stood at $32.8 million in 2021, then rose by 2.85% to $33.7 million in 2022, then rose by 2.97% to $34.7 million in 2023, then grew by 3.03% to $35.7 million in 2024, then grew by 3.66% to $37.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $37.0 million (Q4 2025), $35.7 million (Q4 2024), and $34.7 million (Q4 2023) per Business Quant data.